US 8,574,564 B2Granted

Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity

AssigneeCytos Biotechnology AG

InventorsWolfgang A. Renner, Martin F. Bachmann, Indulis Cielens, Conrad Johannes Coester, Klaus Dietmeier, Sebastian Fuchs, Vania Manolova, Patrik Maurer, Paul Pumpens, Regina Renhofa, Alain Tissot, Yu Zou

Life of this patent

Estimating the term…

patentgrep

Loading patent…

Abstract

The application is related to compositions and methods for the treatment of hypersensitivity, wherein the compositions comprise a particle packaged with immunostimulatory nucleic acids. The compositions of the invention are particularly useful in the treatment of atopic eczema, asthma and IgE-mediated allergy (type I allergy), especially pollen allergy and house dust allergy.

Claims20

Dependent claims

A method of treating a hypersensitivity in an animal, wherein said hypersensitivity is allergy or asthma, wherein said method comprises introducing a composition into said animal, and wherein said composition comprises:

(a) virus-like particle of an RNA bacteriophage Qβ;
and
(b) an unmethylated CpG-containing oligonucleotide consisting essentially of the sequence GGGGGGGGGG GACGATCGTC GGGGGGGGGG (SEQ ID NO:27);
wherein said virus-like particle of an RNA bacteriophage Qβ is packaged with said unmethylated CpG-containing oligonucleotide, wherein said composition does not comprise an allergen, and wherein introduction of said composition treats said hypersensitivity in said animal.

1 more element

Dependencies are inferred from the claim text.

Facts

Application: 12/576,086Filed 8 Oct 2009 · continuation
Priority: 14 Dec 2005
Published: US 2010/0303846 A12 Dec 2010
Granted: 5 Nov 2013
Term ends: Not estimatedThe source records don’t support an estimate.

Classification25 codes

A61K 39/12
Medicinal preparations containing antigens or antibodies: viral antigens
A61K 39/39
Medicinal preparations containing antigens or antibodies: characterised by the immunostimulating additives, e.g. chemical adjuvants
A61K 47/6901
The conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit: conjugates being…
A61K 47/6931
The form being a nanoparticle, e.g. an immuno-nanoparticle: the material constituting the nanoparticle being a polymer

Family

Application60/750,042Us provisional application · filed 14 Dec 2005
Application60/812,592Us provisional application · filed 12 Jun 2006
Application11/638,664Parent of this continuation · filed 14 Dec 2006
US 2010/0303846 A1Pre-grant publication · published 2 Dec 2010
US 2007/0184068 A1Published application
US 8,574,564 B2This patent

From the US filing history. Foreign family members aren’t listed.